AptarGroup stock
ATRNYSEAptarGroup, Inc., HealthcareISIN US0383361039
65Score 65 out of 100, Neutral
Price and trend
68 / 100
Price history
+20% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 73).
The price is 3.5% below its 52-week high. Largest decline in 20 years: 45% (June 2008 to March 2009).
Chart figures for advanced users
- SMA 50$127.75
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$127.79
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)73
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$111.94
- The lowest closing price of the last twelve months.
- Resistance$146.86
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AptarGroup, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $8.98B, is number 17 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.78B (up 5.4% year on year) and earnings of $392.79M (up 4.9%).
- For fiscal 2026, analysts expect on average revenue of $4.01B (up 6.2%) and adjusted earnings per share of $5.55 (down 3.2%).
Show more
- MEQIRI Score 65 out of 100 (Neutral): rank 212 of 714 in Healthcare, median 53.
- The P/E is 34 (Medical (Instruments & Supplies) median 34.8, own median of recent years 29.3).
- Our model puts fair value at $134.51, with the price 6% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 33 years.Capital allocation 58
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
- Earnings turn into cashFree cash flow 110% of earnings over the last 12 months.Fundamentals 85
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and momentum, while growth and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 64 to 65.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $103.47 and expensive above $192.15 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $124.18 (cash-flow model) and $144.83 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $123.93, at 7.8% it would be $150.39.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 9% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 30%, operating 14%, net 10%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 29 Oct 2026EPS reported $1.52 (expected $1.47)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.55+0.8%
- Revenue
- $4.01B+0.9%
- Earnings per share
- $6.20−0.4%
- Revenue
- $4.14B+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +2.2%2026 capital investments of $260 million to $280 million confirmed; the roughly $65 million emergency medicine sales decline was flagged before and the headwind should abate by the fourth quarter.
“For full-year 2026, we continue to expect capital investments to be in the range of $260 million to $280 million and depreciation and amortisation expense to be between $310 million and $320 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $5.36M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Prieur MarcSale
2 Nov 2026, Segment President
- Shares
- 2,000
- Price
- $141.99
- Value
- $283,974
- Vinczeller ShielaSale
2 Sept 2026, Chief Human Resources Officer
- Shares
- 765
- Price
- $130.37
- Value
- $99,733
- Touya GaelSale
27 Aug 2026, Segment Pres., CEO Designate
- Shares
- 3,740
- Price
- $133.76
- Value
- $500,276
Show 6 more
- Prieur MarcSale
4 Aug 2026, Segment President
- Shares
- 3,500
- Price
- $136.26
- Value
- $476,897
- Tanda Stephan B.Sale
3 Aug 2026, President and CEO
- Shares
- 9,838
- Price
- $136.16
- Value
- $1.34M
- Tlili HediSale
3 Aug 2026, Segment President
- Shares
- 8,854
- Price
- $135.00
- Value
- $1.2M
- Prieur MarcSale
9 Jun 2026, Segment President
- Shares
- 5,000
- Price
- $115.58
- Value
- $577,895
- Vinczeller ShielaSale
4 Jun 2026, Chief Human Resources Officer
- Shares
- 3,555
- Price
- $112.61
- Value
- $400,341
- Gong XiangweiSale
26 May 2026, President, Asia
- Shares
- 4,200
- Price
- $116.13
- Value
- $487,765
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AptarGroup
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Baxter InternationalBAX $13.63B47
- Cooper CompaniesCOO $11.97B61
- RepligenRGEN $11.03B51
- AvantorAVTR $10.66B53
- Bausch + LombBLCO $7.62B50
- Asahi Intecc7747.T $6.34B83
- Gan & Lee Pharmaceuticals.603087.SS $6.21B56
- TeleflexTFX $6.2B59
ETFs that hold AptarGroup
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR S&P U.S. Dividend Aristocrats UCITS ETF (Dist)SPYD | 0.36% | 0.35% | €3.62B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.27% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.22% | 0.43% | €2.48B |
Show 5 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.17% | 0.35% | €434.1M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.13% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.10% | 0.35% | €8.19B |
| WisdomTree Global Quality Dividend Growth UCITS ETF USD AccWTEM | 0.05% | 0.38% | €1.5B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.02% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 13 Dec 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.